OTHER
Glucose-dependent Insulinotropic Polypeptide (GIP)
GIP - gut hormone
The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals
Status
Enrolling by invitation
Phase
Not applicable
Enrollment
14
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.
Interventions
Treatment arms and agents.
OTHER
GLP-1 (7-36) amide
gut hormone - GLP-1(7-36)NH2
OTHER
Apomorphine Injectable Solution
used as a tool to induce nausea
OTHER
Saline (0.9% NaCl)
Placebo
Timeline
From registration to results.
First posted
Jul 7, 2026
Study start
May 19, 2026
Primary completion
Nov 30, 2026
Study completion
Apr 28, 2027
Results posted
Not reported
Registry updated
Jul 7, 2026
Outcomes
What the study measures.
Primary outcomes
Change in GLP-1 induced nausea intensity
Time frame · From enrollment to the end of treatment at up to 12 weeks.
The primary endpoint is the change in GLP-1-induced nausea intensity, measured by a 0-100 mm visual analogue scale (VAS), between study visits, with and without GIP infusion.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 60 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Men or women, age of 18-60 years * BMI between 19-27 kg/m2 (both included) * informed consent Exclusion Criteria: * Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months * Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery) * Neurological disorders affecting nausea (e.g. severe migraines and neuropathy) * Any known eating disorders (e.g. anorexia nervosa and bulimia) * Pregnancy or breastfeeding * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (\> 2 times normal values) or present hepatobiliary disease * Kidney disease (estimated glomerular filtration rate (eGFR)\<90 ml/min/1.73 m2) at screening * Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV) * Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes * Any condition that the investigator evaluates would interfere with study participation
Study locations
1 registered sites.
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Center for Clinical Metabolic Research, Herlev-Gentofte Hospital
Hellerup, Denmark
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Glucagon.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center · Opioid Use Disorder · Opioid Abuse and Addiction
Phase 2
Recruiting
200
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.